Quotient

Quotient EBIT/Assets

Delisted

The Operating Income to Assets Ratio (EBIT/Assets) of Quotient (QTNT) as of Nov 9, 2026 is -47.54 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -37.63 % — a change of 26.33% (lower).

EBIT/Assets

-47.54 %

YoY

26.33%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Quotient is 2022 -47.54 % . Operating Income to Assets Ratio (EBIT/Assets) of Quotient was 2021 -37.63 % . It decreases by 26.33% lower compared to the previous year.

The Quotient EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2015
-36.63 USD
Jan 1, 2016
-40.99 USD
Jan 1, 2017
-68.35 USD
Jan 1, 2018
-54.60 USD
Jan 1, 2019
-44.41 USD
Jan 1, 2020
-35.63 USD
Jan 1, 2021
-37.63 USD
Jan 1, 2022
-47.54 USD
The Quotient EBIT/Assets history
YEAREBIT/AssetsYoY
-47.54 %+26.33%
-37.63 %+5.61%
-35.63 %-19.78%
-44.41 %-18.66%
-54.60 %-20.11%
-68.35 %+66.74%
-40.99 %+11.91%
-36.63 %+22.79%
-29.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quotient Stock analysis

What does Quotient do? Quotient Ltd is a biopharmaceutical company headquartered in Eysins, Switzerland. The company was founded in 2007 with the aim of developing innovative technologies in the field of Personalized Medicine. This means that medications and therapies are specifically tailored to the individual needs of patients. Thanks to state-of-the-art production processes, products can be produced quickly and safely. Quotient Ltd has a unique business model based on transfusion technology. This technology allows the company to produce medications quickly and accurately. The different components of the medications are separated and then combined in the required dosage. This means that the medications can be precisely dosed and the risks of side effects minimized. A key focus of Quotient Ltd is the development of therapeutics. Personalized medicine and the fast and safe production of medications are at the center of this area. The transfusion technology enables medications to be produced quickly and flexibly, which is particularly important for rare diseases and personalized therapies. Another important area is the development of diagnostics. These enable diseases to be diagnosed quickly and safely. Based on this diagnosis, suitable therapies are then developed. Quotient Ltd also relies on transfusion technology for this, which enables fast, reliable, and flexible production of diagnostics. In addition to its developed technology and know-how, Quotient Ltd also has its own production facility. Here, all products are produced to the highest standards. The production facility covers an area of approximately 6,000 square meters. The modern facility is equipped with the latest technologies and meets the highest quality standards. Quotient Ltd offers a variety of products, with a special focus on personalized medicine and the fast and safe production of medications and diagnostics. One example is the PDA diagnostic system, which was developed for the fast and accurate diagnosis of autoimmune diseases. The MosaiQ system is another important product that enables fast and reliable production of medications. The success story of Quotient Ltd is closely linked to the development of transfusion technology. The company has succeeded in developing a technology that allows for the fast and safe production of personalized medicine. This technology has made Quotient Ltd a leading company in the field of personalized medicine worldwide. Today, Quotient Ltd employs over 700 people who are constantly working on the further development of personalized medicine and transfusion technology. Quotient is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quotient stock

Operating Income to Assets Ratio (EBIT/Assets) of Quotient is -47.54 % in 2022.

Operating Income to Assets Ratio (EBIT/Assets) of Quotient changed from -37.63 % to -47.54 %, representing a 26.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Quotient since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Quotient with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Quotient

All Key Metrics — Quotient